Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trial
Sheppard JP. et al, (2024), The Lancet Healthy Longevity, 5, e563 - e573
Effect of antihypertensive deprescribing on serious adverse events, mortality, and cardiovascular disease: Long-term follow-up of the OPTiMISE randomised controlled trial
SHEPPARD J. et al, (2024), The Lancet Healthy Longevity
EFFECT OF ANTIHYPERTENSIVE DEPRESCRIBING ON SERIOUS ADVERSE EVENTS, MORTALITY, AND CARDIOVASCULAR DISEASE: LONG-TERM FOLLOW-UP OF THE OPTIMISE RANDOMISED CONTROLLED TRIAL
Sheppard J. et al, (2024), JOURNAL OF HYPERTENSION, 42
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial
Nanchahal J. et al, (2022), The Lancet Rheumatology, 4, e407 - e416
Community-based rehabilitation after knee arthroplasty: A randomised controlled trial with economic evaluations (CORKA trial): ISRCTN: 13517704
Barker K. et al, (2021), Physiotherapy, 113, e1 - e2
Outpatient physiotherapy versus home-based rehabilitation for patients at risk of poor outcomes after knee Arthroplasty: CORKA RCT
Barker KL. et al, (2020), Health Technology Assessment, 24, 1 - 115